2025 Annual Meeting | C76 - Multiple Sclerosis Disease-modifying Treatment

Date Sunday 04/06/25

Time 03:30 PM - 05:30 PM PDT Add To Calendar

Location San Diego Convention Center | 6A

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Veronica P. Cipriani, MD

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be able to identify all current options for disease-modifying treatments for multiple sclerosis; comprehend the mechanism of action of each medication, as well as the potential side effects; judge which DMTs would be appropriate for individual patients with multiple sclerosis; and be able to identify new molecules that being developed for disease-modifying treatment of multiple sclerosis.

This program is supported in part by an educational grant from Novartis

CME Available 2.00 CME credits

Core Competencies Medical Knowledge

Program Level Intermediate

Program Tracks Brain Health

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation, Other

Program Materials Program Evaluations

Event Timeline
03:30 PM - 04:00 PM PDT	Speaker	Introduction Veronica P. Cipriani, MD
04:00 PM - 04:30 PM PDT	Speaker	Medication Options Marwa Kaisey, MD
04:30 PM - 05:00 PM PDT	Speaker	Medication Side Effects Daniel P. Kurz, MD
05:00 PM - 05:30 PM PDT	Speaker	Questions and Answers Veronica P. Cipriani, MD, Daniel P. Kurz, MD, Marwa Kaisey, MD

Faculty Disclosures
Veronica P. Cipriani, MD	Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Cipriani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Cipriani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Pharmaceuticals. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Cipriani has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Cipriani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with Vaccine Injury Compensation Program. Dr. Cipriani has received personal compensation in the range of $500-$4,999 for serving as a Member of Board of Directors with Chicago MS Alliance.
Daniel P. Kurz, MD	An immediate family member of Dr. Kurz has received personal compensation for serving as an employee of Grainger. An immediate family member of Dr. Kurz has stock in Grainger. The institution of Dr. Kurz has received research support from Biogen.
Marwa Kaisey, MD	Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Kaisey has received research support from NMSS.

��ɫ��

��ɫ��